The clinical benefit of GSK2636771, a selective PI3Kβ inhibitor, was also studied for PTEN-deficient solid tumors [46], and trials combining it with paclitaxel are underway for PTEN-deficient gastric cancers using IHC assay (clinicaltrial.gov identifier; NCT02615730). The gene discussed is PTEN; the disease is gastric cancer.